Lyell Immunopharma Quarterly Balance Sheets Chart
Quarterly
|
Annual
Lyell Immunopharma Quarterly Balance Sheets Table
Quarterly
|
Annual
| Unit: USD | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 | 2022-09-30 | 2022-06-30 | 2022-03-31 | 2021-12-31 | 2021-09-30 | 2021-06-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| assets | |||||||||||||||||
| current assets: | |||||||||||||||||
| cash and cash equivalents | 98,804,000 | 120,328,000 | 105,597,000 | 100,299,000 | 133,424,000 | 125,650,000 | 145,647,000 | 286,214,000 | 224,372,000 | 109,426,000 | 123,554,000 | 116,311,000 | 205,739,000 | 222,596,000 | 293,828,000 | 393,504,000 | 564,441,000 |
| marketable securities | 177,986,000 | 180,849,000 | 264,930,000 | 340,248,000 | 357,695,000 | 400,650,000 | 400,576,000 | 289,217,000 | 371,376,000 | 503,343,000 | 516,598,000 | 531,821,000 | 449,825,000 | 391,316,000 | 320,966,000 | ||
| prepaid expenses and other current assets | 5,424,000 | 8,001,000 | 9,067,000 | 9,498,000 | 8,705,000 | 7,865,000 | 8,463,000 | 11,423,000 | 10,662,000 | 11,629,000 | 11,143,000 | 11,613,000 | 11,214,000 | 11,793,000 | 11,492,000 | 12,226,000 | 10,317,000 |
| total current assets | 282,214,000 | 309,178,000 | 379,594,000 | 450,045,000 | 499,824,000 | 534,165,000 | 554,686,000 | 586,854,000 | 606,410,000 | 624,398,000 | 651,295,000 | 659,745,000 | 666,778,000 | 625,705,000 | 626,286,000 | 631,147,000 | 834,840,000 |
| restricted cash | 1,584,000 | 1,688,000 | 1,690,000 | 288,000 | 287,000 | 286,000 | 284,000 | 283,000 | 282,000 | 281,000 | 280,000 | 279,000 | 279,000 | 279,000 | 466,000 | 466,000 | 466,000 |
| marketable securities, non-current | 20,059,000 | 28,949,000 | 13,014,000 | 20,112,000 | 16,506,000 | 22,729,000 | 36,952,000 | 55,255,000 | 70,117,000 | 102,519,000 | 131,438,000 | 224,118,000 | 283,531,000 | ||||
| other investments | 19,000,000 | 19,000,000 | 19,000,000 | 19,000,000 | 19,000,000 | 19,000,000 | 32,001,000 | 32,001,000 | 32,001,000 | 34,924,000 | 44,924,000 | 42,001,000 | 47,001,000 | 47,001,000 | 47,001,000 | 83,448,000 | 83,448,000 |
| property and equipment | 39,115,000 | 44,195,000 | 48,200,000 | 88,047,000 | 93,096,000 | 97,836,000 | 102,654,000 | 108,096,000 | 113,677,000 | 118,600,000 | 123,023,000 | 125,727,000 | 127,559,000 | 125,707,000 | 120,098,000 | 115,857,000 | 109,637,000 |
| operating lease right-of-use assets | 20,951,000 | 23,570,000 | 24,739,000 | 36,662,000 | 37,696,000 | 38,695,000 | 39,663,000 | 40,603,000 | 41,512,000 | 42,390,000 | 43,242,000 | 44,084,000 | 44,907,000 | 45,725,000 | 46,541,000 | ||
| other non-current assets | 2,530,000 | 3,218,000 | 4,622,000 | 5,061,000 | 4,239,000 | 4,238,000 | 4,235,000 | 4,423,000 | 4,520,000 | 4,602,000 | 4,680,000 | 2,914,000 | 3,712,000 | 3,568,000 | 3,483,000 | 2,669,000 | 2,791,000 |
| total assets | 385,453,000 | 429,798,000 | 490,859,000 | 619,215,000 | 654,142,000 | 694,220,000 | 750,029,000 | 794,989,000 | 835,354,000 | 880,450,000 | 937,561,000 | 977,269,000 | 1,021,674,000 | 1,072,103,000 | 1,127,406,000 | 1,198,334,000 | 1,229,867,000 |
| liabilities and stockholders’ equity | |||||||||||||||||
| current liabilities: | |||||||||||||||||
| accounts payable | 3,379,000 | 3,728,000 | 5,366,000 | 3,596,000 | 4,199,000 | 4,895,000 | 4,817,000 | 4,365,000 | 5,805,000 | 5,733,000 | 3,917,000 | 4,795,000 | 4,247,000 | 6,510,000 | 3,207,000 | 3,526,000 | 4,863,000 |
| accrued liabilities and other current liabilities | 27,999,000 | 31,168,000 | 40,411,000 | 29,009,000 | 25,670,000 | 24,914,000 | 28,126,000 | 29,652,000 | 24,832,000 | 22,416,000 | 28,755,000 | 23,568,000 | 21,396,000 | 22,686,000 | 29,057,000 | 25,058,000 | 25,568,000 |
| contingent consideration payable | 5,525,000 | 6,389,000 | 7,600,000 | ||||||||||||||
| total current liabilities | 36,903,000 | 41,285,000 | 53,788,000 | 33,512,000 | 30,879,000 | 32,353,000 | 34,519,000 | 35,064,000 | 34,390,000 | 30,797,000 | 37,028,000 | 51,217,000 | 50,291,000 | 41,055,000 | 46,738,000 | 59,281,000 | 63,663,000 |
| operating lease liabilities, non-current | 46,597,000 | 48,851,000 | 50,994,000 | 51,441,000 | 53,323,000 | 55,159,000 | 56,894,000 | 58,576,000 | 60,221,000 | 61,826,000 | 63,168,000 | 64,636,000 | 66,074,000 | 67,475,000 | 66,650,000 | 65,684,000 | |
| other non-current liabilities | 3,030,000 | 3,141,000 | 3,253,000 | 3,565,000 | 3,439,000 | 3,551,000 | 3,664,000 | 3,776,000 | 3,888,000 | 4,001,000 | 4,113,000 | 4,227,000 | 4,340,000 | 4,453,000 | 4,566,000 | 5,012,000 | 900,000 |
| total liabilities | 86,530,000 | 93,277,000 | 108,035,000 | 88,518,000 | 87,641,000 | 91,063,000 | 95,077,000 | 97,416,000 | 98,499,000 | 96,624,000 | 104,309,000 | 157,243,000 | 153,632,000 | 190,854,000 | 197,619,000 | 211,860,000 | 207,912,000 |
| commitments and contingencies | |||||||||||||||||
| stockholders’ equity: | |||||||||||||||||
| preferred stock, 0.0001 par value; 10,000 shares authorized at june 30, 2025 and december 31, 2024; no shares issued and outstanding at june 30, 2025 and december 31, 2024 | |||||||||||||||||
| common stock | 1,000 | 30,000 | 29,000 | 26,000 | 26,000 | 25,000 | 25,000 | 25,000 | 25,000 | 25,000 | 25,000 | 25,000 | 25,000 | 25,000 | 24,000 | 24,000 | 24,000 |
| additional paid-in capital1 | 1,738,850,000 | ||||||||||||||||
| accumulated other comprehensive income | 57,000 | 158,000 | 291,000 | 760,000 | -1,623,000 | -65,000 | 73,000 | ||||||||||
| accumulated deficit | -1,439,985,000 | -1,397,301,000 | -1,345,106,000 | -1,153,171,000 | -1,108,588,000 | -1,062,779,000 | -1,002,112,000 | -949,182,000 | -898,329,000 | -834,439,000 | -767,480,000 | -759,083,000 | -688,829,000 | -652,506,000 | -584,362,000 | -500,656,000 | -451,781,000 |
| total stockholders’ equity | 298,923,000 | 336,521,000 | 382,824,000 | 530,697,000 | 566,501,000 | 603,157,000 | 654,952,000 | 697,573,000 | 736,855,000 | 783,826,000 | 833,252,000 | 820,026,000 | 868,042,000 | 881,249,000 | 929,787,000 | ||
| total liabilities and stockholders’ equity | 385,453,000 | 429,798,000 | 490,859,000 | 619,215,000 | 654,142,000 | 694,220,000 | 750,029,000 | 794,989,000 | 835,354,000 | 880,450,000 | 937,561,000 | 977,269,000 | 1,021,674,000 | 1,072,103,000 | |||
| preferred stock, 0.0001 par value; 10,000 shares authorized at march 31, 2025 and december 31, 2024; no shares issued and outstanding at march 31, 2025 and december 31, 2024 | |||||||||||||||||
| additional paid-in capital | 1,733,634,000 | 1,727,610,000 | 1,683,082,000 | 1,675,460,000 | 1,666,315,000 | 1,657,133,000 | 1,647,911,000 | 1,637,538,000 | 1,622,119,000 | 1,608,306,000 | 1,589,080,000 | 1,565,197,000 | 1,540,330,000 | 1,515,748,000 | 1,487,171,000 | 1,473,639,000 | |
| success payment liabilities | 411,000 | 907,000 | 1,010,000 | 2,544,000 | 1,576,000 | 1,047,000 | 3,753,000 | 2,648,000 | 4,356,000 | 11,663,000 | 9,222,000 | 5,635,000 | 9,486,000 | 25,116,000 | 25,006,000 | ||
| preferred stock, 0.0001 par value; 10,000 shares authorized at december 31, 2024 and 2023, respectively; no shares issued and outstanding at december 31, 2024 and 2023 | |||||||||||||||||
| preferred stock, 0.0001 par value; 10,000 shares authorized at september 30, 2024 and december 31, 2023; no shares issued and outstanding at september 30, 2024 and december 31, 2023 | |||||||||||||||||
| preferred stock, 0.0001 par value; 10,000 shares authorized at june 30, 2024 and december 31, 2023; no shares issued and outstanding at june 30, 2024 and december 31, 2023 | |||||||||||||||||
| accumulated other comprehensive loss | -397,000 | -404,000 | -94,000 | -1,181,000 | -2,379,000 | -3,879,000 | -7,599,000 | -9,996,000 | -8,351,000 | -6,600,000 | |||||||
| preferred stock, 0.0001 par value; 10,000 shares authorized at march 31, 2024 and december 31, 2023; no shares issued and outstanding at march 31, 2024 and december 31, 2023 | |||||||||||||||||
| preferred stock, 0.0001 par value; 10,000 shares authorized at december 31, 2023 and 2022, respectively; no shares issued and outstanding at december 31, 2023 and 2022 | |||||||||||||||||
| preferred stock, 0.0001 par value; 10,000 shares authorized at september 30, 2023 and december 31, 2022; no shares issued and outstanding at september 30, 2023 and december 31, 2022 | |||||||||||||||||
| preferred stock, 0.0001 par value; 10,000 shares authorized at june 30, 2023 and december 31, 2022; no shares issued and outstanding at june 30, 2023 and december 31, 2022 | |||||||||||||||||
| preferred stock, 0.0001 par value; 10,000 shares authorized at march 31, 2023 and december 31, 2022; no shares issued and outstanding at march 31, 2023 and december 31, 2022 | |||||||||||||||||
| deferred revenue | 11,191,000 | 15,426,000 | 6,224,000 | 4,988,000 | 5,581,000 | 8,226,000 | |||||||||||
| deferred revenue, non-current | 37,163,000 | 32,927,000 | 77,871,000 | 79,665,000 | 81,883,000 | ||||||||||||
| preferred stock, 0.0001 par value; 10,000 shares authorized at december 31, 2022 and 2021, respectively; zero shares issued and outstanding at december 31, 2022 and 2021 | |||||||||||||||||
| preferred stock, 0.0001 par value; 10,000 shares authorized at september 30, 2022 and december 31, 2021; zero shares issued and outstanding at september 30, 2022 and december 31, 2021 | |||||||||||||||||
| preferred stock, 0.0001 par value; 10,000 shares authorized at june 30, 2022 and december 31, 2021; zero shares issued and outstanding at june 30, 2022 and december 31, 2021 | |||||||||||||||||
| preferred stock, 0.0001 par value; 10,000 shares authorized at march 31, 2022 and december 31, 2021; zero shares issued and outstanding at march 31, 2022 and december 31, 2021 | |||||||||||||||||
| liabilities, convertible preferred stock and stockholders’ equity | |||||||||||||||||
| convertible preferred stock | |||||||||||||||||
| stockholders’ equity | |||||||||||||||||
| preferred stock, 0.0001 par value; 10,000 and zero shares authorized at december 31, 2021 and 2020, respectively; zero shares issued and outstanding at december 31, 2021 and 2020 | |||||||||||||||||
| total liabilities, convertible preferred stock and stockholders’ equity | 1,127,406,000 | ||||||||||||||||
| short-term marketable securities | 225,417,000 | 260,082,000 | |||||||||||||||
| long-term marketable securities | 317,511,000 | 150,261,000 | |||||||||||||||
| right-of-use assets | 47,236,000 | 48,424,000 | |||||||||||||||
| liabilities, convertible preferred stock and stockholders' equity | |||||||||||||||||
| stockholders' equity | |||||||||||||||||
| preferred stock, 0.0001 par value; 10,000 and zero shares authorized at september 30, 2021 and december 31, 2020, respectively; zero shares issued and outstanding at september 30, 2021 and december 31, 2020 | |||||||||||||||||
| total stockholders' equity | 986,474,000 | 1,021,955,000 | |||||||||||||||
| total liabilities, convertible preferred stock and stockholders' equity | 1,198,334,000 | 1,229,867,000 | |||||||||||||||
| operating lease liabilities, net of current portion | 61,471,000 | ||||||||||||||||
| deferred revenue, net of current portion | 81,878,000 | ||||||||||||||||
| preferred stock, 0.0001 par value; 10,000 and zero shares authorized at june 30, 2021 and december 31, 2020, respectively; zero shares issued and outstanding at june 30, 2021 and december 31, 2020 |
We provide you with 20 years of balance sheets for Lyell Immunopharma stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as asset and liabilities, payables and receivables, long debts and short debts, cash and inventories, expenses and profits. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Lyell Immunopharma. Explore the full financial landscape of Lyell Immunopharma stock with our expertly curated balance sheets.
The information provided in this report about Lyell Immunopharma stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.